Background

Paradoxical autoimmune reactions (PAR) — including psoriasiform dermatitis, lupus-like syndromes, and vasculitis — affect 5–25% of patients receiving TNF inhibitors (TNFi) for rheumatoid arthritis and spondyloarthropathies. Current pharmacovigilance relies on post-hoc clinical detection, offering no predictive capability. The abruptness of PAR onset suggests underlying bistable dynamics amenable to catastrophe-theoretic modeling.

Hypothesis

We hypothesize that cusp catastrophe models parameterized by pharmacogenomic polygenic interaction scores can predict PAR onset 4–12 weeks before clinical manifestation. Specifically:

1. Control parameters: A polygenic interaction score integrating NAT2 acetylator status, TNFAIP3 risk variants (rs2230926), IRF5 haplotypes, and PTPN22 R620W creates a two-dimensional control surface where (a) cumulative TNFi exposure acts as the normal factor and (b) the polygenic score acts as the splitting factor.

2. State variable: Serum type I interferon (IFN-α) score, measured via a 5-gene signature (MX1, IFIT1, IFI44L, RSAD2, OAS1), represents the immune equilibrium state.

3. Catastrophe prediction: Patients whose trajectories approach the cusp bifurcation set — identifiable via decreasing return rate to equilibrium (critical slowing down) in serial IFN scores — will undergo sudden PAR within 4–12 weeks with >80% sensitivity.

Mathematical Framework

The cusp catastrophe potential is:

$$V(x) = x^4/4 + \alpha x^2/2 + \beta x$$

where $x$ = IFN score deviation from baseline, $\alpha$ = f(cumulative TNFi dose, CYP metabolism), $\beta$ = g(polygenic interaction score). The bifurcation set ${4\alpha^3 + 27\beta^2 = 0}$ defines the critical boundary. Serial IFN measurements approaching this set exhibit characteristic early warning signals: increased variance, increased autocorrelation, and flickering between immune states.

Testable Predictions

1. Patients with NAT2 slow-acetylator + TNFAIP3 risk variant have a splitting factor $|\beta|$ placing them within the bistable region, conferring >3× PAR hazard ratio.
2. Serial IFN score variance increases >2 SD above patient baseline 4–12 weeks before PAR (critical slowing down signal).
3. The cusp model outperforms logistic regression (AUC improvement >0.10) for PAR prediction when pharmacogenomic interactions are included as splitting factors.
4. Patients identified as approaching the bifurcation set who undergo preemptive TNFi dose reduction will have >50% PAR avoidance rate.

Study Design

Prospective cohort, n ≥ 300 TNFi-naïve RA/SpA patients. Pharmacogenomic panel at baseline (NAT2, TNFAIP3, IRF5, PTPN22, CYP3A4). Serial IFN 5-gene score every 4 weeks × 48 weeks. Primary endpoint: PAR occurrence (dermatologic, serologic, or systemic). Cusp catastrophe model fitted via Cobb maximum likelihood method with Bayesian priors from existing pharmacogenomic effect sizes.

Limitations

• Cusp catastrophe assumes two control parameters; higher-dimensional catastrophes (swallowtail, butterfly) may better capture multi-factorial PAR but require larger datasets for identifiability.
• IFN score is a proxy for the true immune state variable; multi-dimensional state representations may improve fidelity.
• Gene-gene epistatic interactions in the polygenic score are computationally intensive and may require regularized interaction terms.
• PAR incidence of 5–25% means modest event counts; Bayesian shrinkage priors are essential to avoid overfitting.
• Generalizability across TNFi molecules (infliximab vs. adalimumab vs. etanercept) needs separate validation given distinct immunogenicity profiles.

Clinical Significance

A validated catastrophe-theoretic early warning system would enable preemptive intervention — dose adjustment, switching, or enhanced monitoring — before irreversible PAR manifestation. Integration of pharmacogenomic stratification at treatment initiation with longitudinal critical slowing down monitoring creates a two-layer predictive framework applicable to any biologic class. This approach bridges dynamical systems theory with precision rheumatology, offering mechanistic insight beyond correlative risk scores.

RheumaAI Research • rheumai.xyz • DeSci Rheumatology